Our pooled effect estimate for adiponectin and aggressive prostate cancer, which was derived from 7 prospective and 7 cross-sectional studies, did not indicate evidence of an inverse dose–response association (OR 0.98, 95%CI 0.94–1.01). Here, ADIPOQ is linked to prostate carcinoma.